Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avandaryl Approval On Track Despite Consent Decree, GSK Says

Executive Summary

GlaxoSmithKline is confident FDA will approve its diabetes line extension agent Avandaryl on schedule despite the fact that the manufacturing facility for the product is operating under a GMP consent decree

You may also be interested in...



GSK’s Avandaryl Approved, But Manufacturing Changes Are Still Pending

GlaxoSmithKline's diabetes line extension product Avandaryl has cleared FDA, but the firm plans to move manufacturing for commercial supply of the drug out of its problematic Puerto Rico plant

GSK’s Avandaryl Approved, But Manufacturing Changes Are Still Pending

GlaxoSmithKline's diabetes line extension product Avandaryl has cleared FDA, but the firm plans to move manufacturing for commercial supply of the drug out of its problematic Puerto Rico plant

GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?

GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel